The majority of preclinical studies and active clinical trials testing FGFR inhibitors as a cancer treatment are in combination with other therapeutics55, including combinational treatments of lapatinib (EGFR/ErbB2 inhibitor)/PD173074 (FGFR1 inhibitor), gefitinib (EGFR inhibitor)/AZD4547 (FGFR1-3 inhibitor), and AEE788 (pan-EGFR inhibitor)/dovitinib (FGFR1/3 inhibitor)26, 52, 55, 56. This evidence concerns the gene FGFR1 and cancer.